Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Pivot, X ^a,c   Felip, E ^b,c  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDICATION; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THORAX RADIOGRAPHY; THYROID FUNCTION TEST; TREATMENT PLANNING; HEAD AND NECK TUMOR; INCIDENCE; PATHOLOGY; PRACTICE GUIDELINE; TUMOR RECURRENCE;

CARCINOMA, SQUAMOUS CELL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 45149118901     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn097     Document Type: Article

References (13)

1. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000; 355: 949-955.
2. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
3. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
4. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
5. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
6. Huguenin P, Beer KT, Allal A et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22: 4613-4621.
7. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 1992; 10: 1245-1251.
8. Zorat PL, Paccagnelia A, Cavaniglia G et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-1717.
9. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
10. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluarouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645.
11. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
12. Vermorken JB, Remener E, van Herpen C et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
13. Vermorken JB, Mesia R, Vega V et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first-line platinum based therapy. Results of a randomized phase III (Extreme) study. ASCO Annual Meeting 2007 (Abstr 6091).